Opko completes its acquisition of Prolor Biotech

|By:, SA News Editor

Opko Health (OPK -1%) says it's completed its acquisition of Prolor Biotech (PBTH).

Under the terms of the deal, each PBTH stockholder will receive 0.9951 shares of OPK.

The acquisition provides OPK with four significant products in Phase III clinical development, as well as a pipeline of important therapeutic and unique diagnostic products in various stages of development.